Liminal BioSciences Inc.
LMNLNASDAQHealthcare
$8.50
+$0.01(+0.12%)
Market Cap$27621005
P/E Ratio—
52W High$8.5
52W Low$3.1
Liminal BioSciences Inc. (LMNL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LMNL · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.40M | $0.64M | $3.32M | $4.90M | $47.37M |
| Cost of Revenue | $0.00M | $0.00M | $2.03M | $2.76M | $38.00M |
| Gross Profit | $0.40M | $0.64M | $1.28M | $2.14M | $9.37M |
| Gross Margin %(computed) | 100.00% | 100.00% | 38.71% | 43.66% | 19.78% |
| Operating Expenses | |||||
| R&D Expenses | $15.30M | $18.35M | $56.83M | $75.11M | $91.67M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $33.16M | $50.27M | $95.38M | $120.40M | $123.20M |
| Operating Income | ($32.98M) | ($49.56M) | ($94.27M) | ($210.63M) | ($113.54M) |
| Operating Margin %(computed) | — | — | — | — | -239.67% |
| Interest Income | $0.00M | $0.00M | $0.45M | $0.00M | $0.31M |
| Interest Expense | $1.08M | $6.33M | $8.72M | $14.06M | $22.37M |
| Income Before Tax | ($29.44M) | ($44.95M) | ($122.34M) | ($234.46M) | ($257.92M) |
| Income Tax Expense | ($0.53M) | $0.12M | ($0.20M) | ($0.24M) | ($20.02M) |
| Net Income | ($28.92M) | ($45.06M) | ($122.14M) | ($234.22M) | ($195.37M) |
| Net Margin %(computed) | — | — | — | — | -412.39% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-341.80 | $-532.66 | $-1443.70 | $-2768.61 | $-2359.49 |
| Wtd Avg Shares | 0.08M | 0.08M | 0.08M | 0.08M | 0.08M |
| EBITDA | ($31.86M) | ($45.21M) | ($105.17M) | ($200.72M) | ($108.08M) |
| EBITDA Margin %(computed) | — | — | — | — | -228.15% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CAD · M
Explore more Liminal BioSciences Inc. data
About Liminal BioSciences Inc. (LMNL) Income Statement
Liminal BioSciences Inc. (LMNL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, LMNL reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.03B) — a net profit margin of -7210.97%.
Frequently asked questions
LMNL · 4 questionsLiminal BioSciences Inc. (LMNL) reported revenue of $0.00B for 2022, down 37.6% year-over-year.
LMNL revenueLMNL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09